NCT05641493招募中1 期
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX208 （BRAF V600E Inhibitor） Combined With Serplulimab（HLX10, Anti-PD-1 Antibody） in Advanced NSCLC Patients With BRAF V600E Mutation.
Shanghai Henlius Biotech1 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2023年2月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 49
- 试验地点
- 1
- 主要终点
- MTD (for phase Ib study)
研究概览
简要总结
An open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 （anti-PD-1 monoclonal antibody）in advanced NSCLC patients with BRAF V600 mutation.
详细描述
This is an open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 （anti-PD-1 monoclonal antibody）in advanced NSCLC patients with BRAF V600 mutation.
For the phase Ib study, HLX208 is administered orally at two dose levels of 600mg BID or 900 mg BID. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks.
For the phase II study, HLX208 is administered orally with the RP2D dose. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 and ≤75 years old of age (in phase Ib study) or ≥18 and ≤80 years old of ag (in phase II study) at the time of informed consent.
- •Signed written informed consent.
- •BRAF V600E mutant advanced solid tumors (in phase Ib study) or advanced NSCLC (in phase II study) patients with positive PD-L1 expression (TPS or TC≥1%).
- •Previous failure of standard therapy, intolerance to standard therapy, lack of standard therapy, or currently unsuitable for standard therapy.
- •Prior systemic anti-neoplastic therapy (chemotherapy, radiotherapy, targeted therapy, or traditional Chinese medicine with anti-neoplastic indications) must have been ≥ 2 weeks from the first dose in this study with treatment-related AE resolved to NCI-CTCAE Grade ≤ 1 (except for alopecia)
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-
- •Expected survival time ≥ 3 months.
- •At least one measurable target lesion per RECIST v1.1 (brain metastasis could not be considered as the only measurable lesion).
- •With normal major organ functions (no blood transfusions or treatment with colony-stimulating factor within 14 days prior to the first dose in this study).
- •Be able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bow
- •Fertile subjects (male or female) must agree to take effective contraceptive measures from the time of signing the ICF until 90 days after the last dose of HLX208 or 6 months after the last dose of HLX
- •Female subjects of childbearing potential must complete a pregnancy test with a negative result within 7 days prior to the first dose.
排除标准
- •For subjects in phase II study: previous treatment with BRAF inhibitors or MEK inhibitors or previous treatment with T cell co-stimulation or immune checkpoint therapy.
- •Known EGFR mutations or ALK rearrangements (except in subjects with EGFR mutations whose disease has progressed after previous EGFR inhibitor treatment).
- •Received strong CYP3A inhibitors or inducers treatment within 1 week prior to the first dose of investigational product.
- •Received major surgery within 28 days prior to the first dose of investigational product. A major surgery is defined as a surgery that takes at least 3 weeks of postoperative recovery before receiving treatment in this study.
- •With uncontrolled pleural effusion, pericardial effusion, or ascites.
- •With symptomatic brain or meningeal metastases (unless the patient has been treated for >3 months, there is no evidence of progression on imaging within 4 weeks prior to the first dose, and the tumor-related clinical symptoms are stable).
- •With active pulmonary tuberculosis. Patients with previous and current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity.
- •With any serious infection requiring systemic anti-infective therapy within 14 days prior to the first dose of the investigational product.
- •History of other malignant tumors (except for cured carcinoma in situ of the cervical or basal cell carcinoma of the skin) within two years prior to the first dose of investigational product.
- •Being positive (+) for hepatitis B surface antigen (HBsAg) or positive (+) for hepatitis B core antibody (HBcAb), and with hepatitis B virus deoxyribonucleic acid (HBV-DNA) ≥ 2500 copies/mL or 500 IU/mL.
- •Being positive (+) for HCV RNA.
- •Being positive (+) human immunodeficiency virus (HIV) antibody.
- •History of serious cardiovascular and cerebrovascular diseases.
- •Systemic treatment with corticosteroids (> 10 mg/day prednisone or equivalent) or other immunosuppressive agents within 14 days prior to the first dose of the investigational product or during the study. In the absence of active autoimmune disease, subjects are allowed to use inhaled or topical steroids, or adrenal hormone replacement therapy at an effective dose equivalent to ≤10 mg/day prednisone.
- •Known active or suspected autoimmune diseases. Subjects with autoimmune related hypothyroidism receiving thyroid hormone replacement therapy are allowed to participate in the study. Subjects with stable type 1 diabetes receiving insulin therapy are allowed to participate in the study.
- •Known alcohol of or drug abuse.
- •Pregnant or lactating women.
- •Received live vaccine within 28 days prior to the first dose of investigational product.
- •Have other conditions not suitable for inclusion as judged by the investigator.
结局指标
主要结局
MTD (for phase Ib study)
时间窗: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
The maximum tolerated dose of HLX208 combined with HLX10.
ORR (for phase II study)
时间窗: up to approximately up to 24 months
Objective response rate assessed by the investigator per RECIST 1.1.
DLT (for phase Ib study)
时间窗: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
The proportion of patients experiencing dose limiting toxicity (DLT) events.
次要结局
- DCR(approximately up to 24 months)
- PFS(approximately up to 36 months)
- TTR(approximately up to 24 months)
- DOR(approximately up to 24 months)
- OS(approximately up to 48 months)
- 12-month PFS rate(12 months)
- AUC0-T(From First administration of HLX 208 to 12 weeks.)
- Cmax(From First administration of HLX 208 to 12 weeks.)
- Tmax(From First administration of HLX 208 to 12 weeks.)
- 6-month PFS rate(6 months)
- AUC0-∞(From First administration of HLX 208 to 12 weeks.)
- 12-month OS rate(12 months)
- 6-month OS rate(6 months)
- AUCss(From First administration of HLX 208 to 12 weeks.)
- SAE(approximately up to 48 months)
- t1/2(From First administration of HLX 208 to 12 weeks.)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid TumorsLocally Advanced or Metastatic Solid Tumors Harboring KRAS G12C MutationNCT06435455Suzhou Genhouse Bio Co., Ltd.126
已完成
1 期
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid TumorsAdvanced Solid TumorNCT06139211Shanghai Junshi Bioscience Co., Ltd.66
已完成
1 期
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor PatientsLocally Advanced or Metastatic Solid TumorsNCT05830539InxMed (Shanghai) Co., Ltd.68
招募中
1 期
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLCNSCLCNCT05994131InxMed (Shanghai) Co., Ltd.110
已完成
1 期
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung CancerAdvanced Solid TumoursNCT03421353AstraZeneca76